Detalle Publicación

ARTÍCULO
B-cell regeneration profile and minimal residual disease status in bone marrow of treated multiple myeloma patients
Autores: Mendonca-de-Pontes, R.; Flores-Montero, J.; Sanoja-Flores, L.; Puig, N.; Pessoa-de-Magalhaes, R. J.; Corral-Mateos, A.; Salgado, A. B. ; Garcia-Sanchez, O.; Perez-Moran, J.; Mateos, M. V.; Burgos Rodríguez, Leire; Paiva, B.; te-Marvelde, J.; van-der-Velden, V. H. J.; Aguilar, C.; Barez, A.; Garcia-Mateo, A.; Labrador, J.; Leoz, P.; Aguilera-Sanz, C.; Durie, B.; van-Dongen, J. J. M. (Autor de correspondencia); Maiolino, A.; Sobral-da-Costa, E.; Orfao, A. (Autor de correspondencia)
Título de la revista: CANCERS
ISSN: 2072-6694
Volumen: 13
Número: 7
Páginas: 1704
Fecha de publicación: 2021
Lugar: WOS
Resumen:
Simple Summary B-cell regeneration during therapy has been associated with the outcome of multiple myeloma (MM) patients. However, the effects of therapy and hemodilution in bone marrow (BM) B-cell recovery have not been systematically evaluated. Here, we show that hemodilution is present in a significant fraction of MM BM samples, leading to lower total B-cell, B-cell precursor (BCP), and normal plasma cell (nPC) counts. Among MM BM samples, decreased percentages (vs. healthy donors) of BCP, transitional/naive B-cell (TBC/NBC) and nPC populations were observed at diagnosis. BM BCP, but not TBC/NBC, increased after induction therapy. At day+100 post-autolo-gous stem cell transplantation, a greater increase in BCP with recovered TBC/NBC numbers but persistently low memory B-cell and nPC counts were found. At the end of therapy, complete response (CR) BM samples showed higher CD19(-) nPC counts vs. non-CR specimens with no clear association between BM B-cell regeneration profiles and patient outcomes. B-cell regeneration during therapy has been considered as a strong prognostic factor in multiple myeloma (MM). However, the effects of therapy and hemodilution in bone marrow (BM) B-cell recovery have not been systematically evaluated during follow-up. MM (n = 177) and adult (>= 50y) healthy donor (HD; n = 14) BM samples were studied by next-generation flow (NGF) to simultaneously assess measurable residual disease (MRD) and residual normal B-cell populations. BM hemodilution was detected in 41 out of 177 (23%) patient samples, leading to lower total B-cell, B-cell precursor (BCP) and normal plasma cell (nPC) counts. Among MM BM, decreased percentages (vs. HD) of BCP, transitional/naive B-cell (TBC/NBC) and nPC populations were observed at diagnosis. BM BCP increased after induction therapy, whereas TBC/NBC counts remained abnormally low. At day+100 postautologous stem cell transplantation, a greater increase in BCP with recovered TBC/NBC cell numbers but persistently low memory B-cell and nPC counts were found. At the end of therapy, complete response (CR) BM samples showed higher CD19(-) nPC counts vs. non-CR specimens. MRD positivity was associated with higher BCP and nPC percentages. Hemodilution showed a negative impact on BM B-cell distribution. Different BM B-cell regeneration profiles are present in MM at diagnosis and after therapy with no significant association with patient outcome.